Prescription Digital Therapeutics: Reimagining Care in Behavior-Driven Conditions

A distinguished panel provides an overview of what digital therapeutics (DTx) and prescription digital therapeutics (PDTs) are and how they’re used in behavioral health treatment.

Arwen Podesta, MD; Timothy Aungst, PharmD; and Scottle Whittle, MD, explain the considerations they think about before using or prescribing DTx and PDTs.

Clinicians, pharmacists, and payers discuss how DTx and PDTs are monitored—for access, efficacy, adherence, and more.

Scott Whittle, MD, uses his knowledge and experiences as a payer—with the help of the other panelists—to explain how the FDA uses gathered evidence to make decisions on approvals for PDTs.

Medical authorities detail how PDTs are compared with other, more conventional treatment modalities in behavioral health.

Drs Whittle and Podesta discuss the durability and stability of DTx and PDT treatment.

Scott Whittle, MD, and Arwen Podesta, MD, confer about cost savings from digital therapeutics and prescription digital therapeutics from payer and provider perspectives.

A panel of specialists focus on how real-world evidence affects the use and acceptance of digital therapeutics and prescription digital therapeutics, as well as FDA approvals.

Drs Podesta and Aungst elaborate on DTx and PDT access and the impact these therapeutics can have in the behavioral health treatment landscape.

Three doctors discuss whether PDTs should be covered as a pharmacy benefit or medical benefit.

Our panel concludes with their final thoughts on using DTx and PDT management.